Avatar Posted by worldpharmanews 282 days ago (http://www.worldpharmanews.com)
Category: Clinical Trials | Tags: astrazeneca recentin avastin cediranib
AstraZeneca today announced that its HORIZON III Phase II/III head-to-head study of RECENTINâ„¢ (cediranib, AZD2171) with chemotherapy versus bevacizumab (Avastinâ„¢) with chemotherapy in patients with first line metastatic colorectal cancer (CRC) will be progressing directly into Phase III at 20mg. Patients will also continue to be recruited at 20mg into the first line CRC HORIZON II study of RECENTIN with chemotherapy versus chemotherapy alone.
Discuss   Add this link to...  Bury

Comments Who Voted Related Links


News/Blogroll [ alliConnect | BioJobBlog | CNTO411 | Corey Nahman | eDrugSearch | Drug Injury Watch | EyeOnFDA | Forbes ScienceBiz | Healthy Skepticism | JNJ BTW | medGadget | Medical 2.0 | Pharma's Market at CNBC | PharmaFraud | PharmaGossip | Pharmalot | Polish Pharma Market | The Shark Report | World Pharma News | WSJ Health Blog ]
Pharmaceutical Companies [ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]

About | Buttons | Contact | Terms and Conditions
Concept and Design by World Pharma News (.com) Project | Powered by Pligg based on PHP/MySQL.
Submit to World Pharma News .net